UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12

BACKGROUND/AIMS: To study the effectiveness and clinical relevance of eyes treated with good (better than 6/12 or >70 Early Treatment Diabetic Retinopathy Study letters) visual acuity (VA) when initiating treatment with ranibizumab for neovascular age-related macular degeneration (nAMD) in the UK...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Ophthalmol
Main Authors: Lee, Aaron Y, Lee, Cecilia S, Butt, Thomas, Xing, Wen, Johnston, Robert L, Chakravarthy, Usha, Egan, Catherine, Akerele, Toks, McKibbin, Martin, Downey, Louise, Natha, Salim, Bailey, Clare, Khan, Rehna, Antcliff, Richard, Varma, Atul, Kumar, Vineeth, Tsaloumas, Marie, Mandal, Kaveri, Liew, Gerald, Keane, Pearse A, Sim, Dawn, Bunce, Catey, Tufail, Adnan
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560462/
https://ncbi.nlm.nih.gov/pubmed/25680619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2014-306229
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki